Scalper1 News
Big-cap biotech Alexion Pharmaceuticals (ALXN) beat Q4 estimates but reported lower than expected guidance Thursday as it announced a change of leadership. Vertex Pharmaceuticals (VRTX) and Celgene (CELG) also moved on new earnings reports. Alexion’s sales rose 36% over the year-earlier quarter to $599 million, more than $8 million ahead of analysts’ consensus. Profit excluding one-time items gained 49% to $1.30 a share, beating estimates by a Scalper1 News
Scalper1 News